Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Co.'s product candidate etripamil is a short-acting calcium channel blocker that Co. designed as a rapid-onset nasal spray to be self-administered by patients. Co. is developing etripamil for the treatment of specific arrhythmias with a lead indication to treat paroxysmal supraventricular tachycardia, with subsequent indications to treat atrial fibrillation and rapid ventricular rate and other cardiovascular indications. The MIST stock yearly return is shown above.
The yearly return on the MIST stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MIST annual return calculation with any dividends reinvested as applicable (on ex-dates).
|